Disease · MONDO_0019086
Trials55
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
1 to 20 of 55
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03189719 | First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) | Phase 3 | 749 | 2021-07-06 | Esophageal Neoplasms | CISPLATIN, FLUOROURACIL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00655876 | Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | Phase 3 | 344 | 2018-03-14 | Esophageal Cancer | CETUXIMAB, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00590031 | Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. | Phase 2 | 61 | 2016-01-25 | Esophageal Carcinoma | CISPLATIN, IRINOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT00193128 | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer | Phase 1/2 | 59 | 2013-05-13 | Esophagus Cancer | CAPECITABINE, DOCETAXEL, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03449030 | A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC) | Phase 1 | 31 | 2021-03-22 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TAK-164 | Its record names the disease | ClinicalTrials.gov |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | Phase 1/2 | 9 | 2023-05-31 | Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas | DECITABINE, PEMBROLIZUMAB, TETRAHYDROURIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00570531 | Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma | Phase 2 | 6 | 2015-01-12 | Loco-regional Esophageal Cancer | BEVACIZUMAB, CISPLATIN, FLUOROURACIL, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | Phase 1/2 | 3 | 2022-04-05 | Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal | PLICAMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). | Phase 3 | 863 | Metastatic Esophageal Squamous Cell Carcinoma | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05569668 | Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma | 826 | Esophagus Cancer | CISPLATIN, DOCETAXEL, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | ||
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | 740 | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | PATRITUMAB DERUXTECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | Phase 3 | 703 | Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC) | CISPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, LEVOLEUCOVORIN, OXALIPLATIN, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Phase 1/2 | 560 | Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer | FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PEMBROLIZUMAB, PETOSEMTAMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02279134 | Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma | Phase 2/3 | 360 | Esophageal Neoplasms, Esophageal Cancer | CISPLATIN, NEDAPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00686114 | Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer | Phase 3 | 344 | Esophageal Cancer | CISPLATIN, ERLOTINIB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT01107639 | Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | Phase 3 | 297 | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | CETUXIMAB, CISPLATIN, DOCETAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00509561 | Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer | Phase 2/3 | 259 | Esophageal Cancer | CAPECITABINE, CETUXIMAB, CISPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01608464 | Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer | Phase 2 | 170 | Carcinoma of Esophagus | CISPLATIN, DOCETAXEL, FLUOROURACIL, IRINOTECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT03308552 | Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02 | Phase 3 | 164 | Esophageal Neoplasms | PACLITAXEL, PLATINUM | Its record names the disease | ClinicalTrials.gov | |
| NCT05508659 | A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors | Phase 1/2 | 128 | Advanced Solid Tumors | DUVELISIB, ENLONSTOBART | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019086/trials